Positive correlation of serum resistin level with peripheral artery disease in patients with chronic kidney disease stage 3 to 5

Xin Ning Ng, Chi Chong Tang, Chih Hsien Wang, Jen Pi Tsai, Bang Gee Hsu

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Chronic kidney disease (CKD) is associated with higher risk of cardiovascular disease-related ischemic events, which includes peripheral arterial disease (PAD). PAD is a strong predictor of future cardiovascular events, which can cause significant morbidity and mortality. Resistin has been found to be involved in pathological processes leading to CVD. Therefore, we aim to investigate whether resistin level is correlated with PAD in patients with non-dialysis CKD stage 3 to 5. There were 240 CKD patients enrolled in this study. Ankle-brachial index (ABI) values were measured using the automated oscillometric method. An ABI value < 0.9 defined the low ABI group. Serum levels of human resistin were determined using a commercially available enzyme immunoassay. Thirty CKD patients (12.5%) were included in the low ABI group. Patients in the low ABI group were older and had higher resistin levels as well as higher diabetes mellitus, hypertension and habit of smoking, and lower estimated glomerular filtration rate than patients in the normal ABI group. After the adjustment for factors that were significantly associated with PAD by multivariate logistic regression analysis, age and serum resistin level were independent predictors of PAD. A high serum resistin level is an independent predictor of PAD in non-dialysis CKD stage 3 to 5.

Original languageEnglish
Article number12746
JournalInternational Journal of Environmental Research and Public Health
Volume18
Issue number23
DOIs
StatePublished - 1 Dec 2021

Keywords

  • Ankle-brachial index
  • Chronic kidney disease
  • Peripheral arterial disease
  • Resistin

Fingerprint

Dive into the research topics of 'Positive correlation of serum resistin level with peripheral artery disease in patients with chronic kidney disease stage 3 to 5'. Together they form a unique fingerprint.

Cite this